Trials / Completed
CompletedNCT06068842
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
International Real-World Study of MET Overexpression in Patients With Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 579 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC. Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months. There is no additional burden for participants in this trial.
Conditions
Timeline
- Start date
- 2023-11-03
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2023-10-05
- Last updated
- 2025-01-29
Locations
19 sites across 12 countries: Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Spain, Switzerland, Taiwan, United Arab Emirates, United Kingdom
Source: ClinicalTrials.gov record NCT06068842. Inclusion in this directory is not an endorsement.